Yuhan Corporation Wins Minister of Health and Welfare Award for Innovative Pharmaceutical Companies
Nov 28, 2025
Yuhan Corporation (CEO Cho Wook-je) won the Minister of Health and Welfare Award at the '2025 Health Industry Performance Exchange Meeting'. Yuhan Corporation obtained the first FDA product approval for a Korean anticancer drug for the third generation of non-small cell lung cancer 'lasertinib' (domestic product name 'Leklaza') developed with domestic technology.
Hosted by the Ministry of Health and Welfare and organized by the Korea Health Industry Promotion Agency, the event was held with a ceremony to celebrate the 30th anniversary of the R&D of health care, as well as awarding awards for merit and presentation of representation. In the afternoon, each session shared examples of successful global technology transfer and overseas expansion, commercialization and cooperation cases of technology, and recent performance of medical devices.
Innovative pharmaceutical companies are a system in which the government examines and certifies domestic pharmaceutical companies with R&D-oriented innovation capabilities such as new drug development and platform technology construction. Among them, companies that have contributed to the improvement of public health and the development of the pharmaceutical industry are selected and commended every year.
At the event, Lee Joon-hyung, director of Yuhan's R&D strategy team, held a meeting to present the results of Yuhan's open innovation and 'Lekraza'.The background of the introduction of open innovation, such as improving the success rate of new drug development, and the success stories of Lecraza through this were announced. This open innovation, along with partner organizations, increased global competitiveness to lead to changes in the ecosystem of the Korean pharmaceutical industry, and announced that the major follow-up clinical tasks currently underway are also the achievements of open innovation.
Hosted by the Ministry of Health and Welfare and organized by the Korea Health Industry Promotion Agency, the event was held with a ceremony to celebrate the 30th anniversary of the R&D of health care, as well as awarding awards for merit and presentation of representation. In the afternoon, each session shared examples of successful global technology transfer and overseas expansion, commercialization and cooperation cases of technology, and recent performance of medical devices.
Innovative pharmaceutical companies are a system in which the government examines and certifies domestic pharmaceutical companies with R&D-oriented innovation capabilities such as new drug development and platform technology construction. Among them, companies that have contributed to the improvement of public health and the development of the pharmaceutical industry are selected and commended every year.
At the event, Lee Joon-hyung, director of Yuhan's R&D strategy team, held a meeting to present the results of Yuhan's open innovation and 'Lekraza'.The background of the introduction of open innovation, such as improving the success rate of new drug development, and the success stories of Lecraza through this were announced. This open innovation, along with partner organizations, increased global competitiveness to lead to changes in the ecosystem of the Korean pharmaceutical industry, and announced that the major follow-up clinical tasks currently underway are also the achievements of open innovation.
|
This article was translated by Naver AI translator.
